FDA Approved New Injectable for Multiple Myeloma
Adults with multiple myeloma have a new subcutaneous delivery option for managing their condition.
Updated on Sept. 30, 2026 in Cancer
In July 2026, the FDA approved isatuximab-irfc for subcutaneous injection to help manage multiple myeloma. The approval introduces a new administration method for patients utilizing the CirCLIQ on-body delivery system.
Why it matters
This approval offers a new delivery mechanism for patients managing multiple myeloma, potentially simplifying the administration process for those requiring ongoing care. It marks an evolution in how patients access established treatments for this blood cell cancer.
The FDA granted approval for isatuximab-irfc as a subcutaneous therapy based on regulatory review of its safety and delivery profile. The assessment confirmed the clinical utility of the CirCLIQ on-body delivery system for patient administration.
The players
FDA
The federal agency responsible for protecting public health by ensuring the safety and efficacy of human drugs and medical devices.
The details
Isatuximab-irfc works by targeting specific proteins on the surface of myeloma cells, effectively labeling them for destruction by the patient's own immune system. By shifting from traditional intravenous infusion to the CirCLIQ on-body delivery system, the drug allows for subcutaneous administration. This method uses an automated system to deliver the medication into the fatty tissue beneath the skin rather than directly into the bloodstream.
Timeline
The FDA approved isatuximab-irfc for subcutaneous injection in July 2026.
Health Landscape
The introduction of subcutaneous delivery for multiple myeloma therapies reflects a broader trend toward patient-centered administration technologies. This development shifts the standard of care from traditional infusion centers toward more flexible, device-assisted delivery methods.
Patients currently managing multiple myeloma may wish to speak with their oncologist to determine if this new subcutaneous administration method is appropriate for their specific treatment plan. It is important to discuss how this delivery system aligns with your existing care routine and what monitoring might be required.
The takeaway
This approval represents a meaningful change in how multiple myeloma therapies are delivered to patients. If you are undergoing treatment, consider asking your physician how new, device-assisted delivery methods could integrate into your long-term management plan.
Further reading
Learn more about the latest developments in blood cancer care in our Cancer section.
Source note: This article includes information reported by OncLive.
